Data gaps limit the translational potential of preclinical research

Science Translational Medicine

Volumn 8, Issue 320, 2016, Pages

  Kleiman, Robin J ^a   Ehlers, Michael D ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ACCESS TO INFORMATION; DATA BASE; DRUG DOSE; DRUG EXPOSURE; DRUG FORMULATION; DRUG IDENTIFICATION; DRUG INFORMATION; DRUG PENETRATION; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; EXPERIMENTAL STUDY; HUMAN; INFORMATION PROCESSING; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; METHODOLOGY; NEUROSCIENCE; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; PUBLICATION; REVIEW; TRANSLATIONAL RESEARCH; ANIMAL; PRECLINICAL STUDY; STATISTICS;

ANIMALS; DATABASES AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; STATISTICS AS TOPIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84954547012     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aac9888     Document Type: Review

References (32)

1. A. Reichel, Addressing central nervous system (CNS) penetration in drug discovery: Basics and implications of the evolving new concept. Chem. Biodivers. 6, 2030-2049 (2009).
2. F. Prinz, T. Schlange, K. Asadullah, Believe it or not: How much can we rely on published data on potential drug targets? Nat. Rev. Drug Discov. 10, 712 (2011).
3. C. G. Begley, L. M. Ellis, Drug development: Raise standards for preclinical cancer research. Nature 483, 531-533 (2012).
4. P. Nair, Second act: Drug repurposing gets a boost as academic researchers join the search for novel uses of existing drugs. Proc. Natl. Acad. Sci. U.S.A. 110, 2430-2432 (2013).
5. T. I. Oprea, J. Mestres, Drug repurposing: Far beyond new targets for old drugs. AAPS J. 14, 759-763 (2012).
6. S. M. Strittmatter, Overcoming drug development bottlenecks with repurposing: Old drugs learn new tricks. Nat. Med. 20, 590-591 (2014).
7. K. Xu, T. R. Coté, Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases. Brief. Bioinform. 12, 341-345 (2011).
8. X. Bosch, European researchers, drug companies join forces against rare diseases. JAMA 294, 2014-2015 (2005).
9. F. S. Collins, Mining for therapeutic gold. Nat. Rev. Drug Discov. 10, 397 (2011).
10. P. Vallance, P. Williams, C. Dollery, The future is much closer collaboration between the pharmaceutical industry and academic medical centers. Clin. Pharmacol. Ther. 87, 525-527 (2010).
11. A. Corbett, J. Pickett, A. Burns, J. Corcoran, S. B. Dunnett, P. Edison, J. J. Hagan, C. Holmes, E. Jones, C. Katona, I. Kearns, P. Kehoe, A. Mudher, A. Passmore, N. Shepherd, F. Walsh, C. Ballard, Drug repositioning for Alzheimer's disease. Nat. Rev. Drug Discov. 11, 833-846 (2012).
12. J. L. Goldstein, M. S. Brown, A century of cholesterol and coronaries: From plaques to genes to statins. Cell 161, 161-172 (2015).
13. A. M. Malfitano, G. Marasco, M. C. Proto, C. Laezza, P. Gazzerro, M. Bifulco, Statins in neurological disorders: An overview and update. Pharmacol. Res. 88, 74-83 (2014).
14. T. Kurata, K. Miyazaki, M. Kozuki, N. Morimoto, Y. Ohta, Y. Ikeda, K. Abe, Progressive neurovascular disturbances in the cerebral cortex of Alzheimer's disease-model mice: Protection by atorvastatin and pitavastatin. Neuroscience 197, 358-368 (2011).
15. H. Kurinami, N. Sato, M. Shinohara, D. Takeuchi, S. Takeda, M. Shimamura, T. Ogihara, R. Morishita, Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model. Int. J. Mol. Med. 21, 531-537 (2008).
16. M. Shinohara, N. Sato, H. Kurinami, D. Takeuchi, S. Takeda, M. Shimamura, T. Yamashita, Y. Uchiyama, H. Rakugi, R. Morishita, Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance. J. Biol. Chem. 285, 22091-22102 (2010).
17. G. J. Siegel, N. B. Chauhan, D. L. Feinstein, G. Li, E. B. Larson, J. C. Breitner, T. J. Montine, Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 71, 383, author reply 383 (2008).
18. X.-K. Tong, C. Lecrux, P. Rosa-Neto, E. Hamel, Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. J. Neurosci. 32, 4705-4715 (2012).
19. X. K. Tong, N.Nicolakakis, P. Fernandes, B. Ongali, J. Brouillette, R. Quirion, E. Hamel, Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol. Dis. 35, 406-414 (2009).
20. E. K. Osterweil, S. C. Chuang, A. A. Chubykin, M. Sidorov, R. Bianchi, R. K. Wong, M. F. Bear, Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 77, 243-250 (2013).
21. C. M. Buchovecky, S. D. Turley, H. M. Brown, S. M. Kyle, J. G. McDonald, B. Liu, A. A. Pieper, W. Huang, D. M. Katz, D. W. Russell, J. Shendure, M. J. Justice, A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome. Nat. Genet. 45, 1013-1020 (2013).
22. M. J. Justice, C. M. Buchovecky, S. M. Kyle, A. Djukic, A role for metabolism in Rett syndrome pathogenesis: New clinical findings and potential treatment targets. Rare Dis. 1, e27265 (2013).
23. F. Scicchitano, A. Constanti, R. Citraro, G. De Sarro, E. Russo, Statins and epilepsy: Preclinical studies, clinical trials and statin-anticonvulsant drug interactions. Curr. Drug Targets 16, 747-756 (2015).
24. M. L. Ferlazzo, L. Sonzogni, A. Granzotto, L. Bodgi, O. Lartin, C. Devic, G. Vogin, S. Pereira, N. Foray, Mutations of the Huntington's disease protein impact on the ATM-dependent signaling and repair pathways of the radiation-induced DNA double-strand breaks: Corrective effect of statins and bisphosphonates. Mol. Neurobiol. 49, 1200-1211 (2014).
25. E. K. Tan, L. C. Tan, Holding on to statins in Parkinson disease. Neurology 81, 406-407 (2013).
26. B. Friedman, A. Lahad, Y. Dresner, S. Vinker, Long-term statin use and the risk of Parkinson's disease. Am. J. Manag. Care 19, 626-632 (2013).
27. M. S. Elkind, Stroke: A step closer to statin therapy for stroke? Nat. Rev. Neurol. 9, 242-244 (2013).
28. E. E. Abrahamson, M. D. Ikonomovic, C. E. Dixon, S. T. DeKosky, Simvastatin therapy prevents brain trauma-induced increases in beta-amyloid peptide levels. Ann. Neurol. 66, 407-414 (2009).
29. E. F. Wible, D. T. Laskowitz, Statins in traumatic brain injury. Neurotherapeutics 7, 62-73 (2010).
30. S. Sierra, M. C. Ramos, P. Molina, C. Esteo, J. A. Vázquez, J. S. Burgos, Statins as neuroprotectants: A comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death. J. Alzheimers Dis. 23, 307-318 (2011).
31. W. G. Wood, G. P. Eckert, U. Igbavboa, W. E. Müller, Statins and neuroprotection: A prescription to move the field forward. Ann. N. Y. Acad. Sci. 1199, 69-76 (2010).
32. W. G. Wood, W. E. Müller, G. P. Eckert, Statins and neuroprotection: Basic pharmacology needed. Mol. Neurobiol. 50, 214-220 (2014).